With the increased threat of bioterrorism, the pursuit of safer and more effective therapies has taken on new importance. LigoCyte’s expertise in the areas of cell communication and mucosal immunity gives the company a strategic advantage in biodefense research and development.

Current biodefense vaccines cover only a small fraction of potential biowarfare agents and typically suffer from efficacy or safety issues. LigoCyte’s unique development strategy is designed to target both the innate and adaptive immune systems, delivering the next generation of biodefense-related drugs and vaccines. LigoCyte is able to develop products that stand alone or work in combination, providing both antigenic specificity for individual agents as well as broad immune enhancement against a range of potential biowarfare pathogens.